Analyst Douglas Tsao of H.C. Wainwright reiterated a Buy rating on Immunovant (IMVT – Research Report), retaining the price target of $51.00.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Douglas Tsao’s rating is based on the potential of Immunovant’s lead asset, IMVT-1402, which is moving into pivotal studies for conditions such as Graves’ disease and difficult-to-treat rheumatoid arthritis. These are areas with unmet medical needs and less competition, offering a strategic opportunity for the company. Additionally, the company’s focus on self-administration could appeal to patients and payers by reducing the need for clinical visits and associated costs. Moreover, Immunovant’s financial position, bolstered by a significant cash balance, is expected to support the completion of these late-stage studies. The upcoming readouts from the batoclimab trial in myasthenia gravis and chronic inflammatory demyelinating polyneuropathy could provide further insights into the efficacy of deeper IgG reduction, which has been a topic of interest in clinical circles.
Tsao covers the Healthcare sector, focusing on stocks such as Protagonist Therapeutics, Cabaletta Bio, and Disc Medicine. According to TipRanks, Tsao has an average return of 11.9% and a 42.57% success rate on recommended stocks.
In another report released yesterday, LifeSci Capital also maintained a Buy rating on the stock with a $50.00 price target.